Conjugate Or Complex Of Monoclonal Or Polyclonal Antibody, Immunoglobulin, Or Fragment Thereof With Nonimmunoglobulin Material Patents (Class 424/178.1)
Abstract: Provided is a matrix carrier composition for use in pharmaceutical delivery system, the composition comprising an intermolecular association of at least a first solid phase comprising nanoparticles having hydrophobic surface, wherein the size of the nanoparticles is in the range of about 5-1000 nm, a second solid phase, comprising a biopolymer having hydrophilic and hydrophobic parts, and a continuous phase comprising oil associated with the first and said second solid phases.
Abstract: Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species.
Type:
Grant
Filed:
March 2, 2012
Date of Patent:
November 22, 2016
Assignee:
Zymeworks Inc.
Inventors:
Surjit Bhimarao Dixit, Igor Edmundo Paolo D'Angelo, David Kai Yuen Poon
Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.
Type:
Grant
Filed:
September 3, 2015
Date of Patent:
November 15, 2016
Assignee:
Immunomedics, Inc.
Inventors:
David M. Goldenberg, Serengulam V. Govindan
Abstract: The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
Type:
Grant
Filed:
April 1, 2015
Date of Patent:
November 15, 2016
Assignee:
Immunomedics, Inc.
Inventors:
Serengulam V. Govindan, David M. Goldenberg
Abstract: The present invention is directed to novel non-invasive diagnostic tools/compounds to image cancers, especially, melanoma, including metastatic melanoma in vivo. The present compounds exhibit enhanced uptake in cancerous cells and tissue and decreased renal uptake in kidney, evidencing favorable pharmacokinetics of compounds of the present invention. The compounds according to the present invention represent an advance in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are also useful for initiating therapy for melanoma as well as monitor patients' response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
Abstract: Embodiments of the present invention illustrate methods of preventing transplantation rejection. In certain embodiments, a subject in need of an organ or non-organ transplantation can be pretreated with an AAT composition to reduce the incidence of transplantion rejection in the subject. Other embodiments include treating a subject with a composition including AAT before, during or after plastic surgery.
Type:
Grant
Filed:
March 27, 2014
Date of Patent:
November 8, 2016
Assignee:
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Abstract: A method of preparing an antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex comprises the steps of (a) preparing an antibody or antibody fragment; (b) mixing said antibody or antibody fragment with a cationic liposome to form a cationic immunoliposome or with a cationic polymer to form a polyplex; and (c) mixing said cationic immunoliposome or said polyplex with a therapeutic or diagnostic agent to form said antibody- or antibody fragment-targeted cationic immunoliposome or polymer complex.
Abstract: Antibodies which bind an antigen of the bone marrow neovasculature in leukemia patients, for use in treatment and diagnosis of leukemia, in particular the treatment and diagnosis of acute myeloid leukemia (AML).
Type:
Grant
Filed:
March 19, 2014
Date of Patent:
September 20, 2016
Assignee:
Philochem AG
Inventors:
Manuela Kaspar, Christoph Schliemann, Dario Neri
Abstract: The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
Type:
Grant
Filed:
April 26, 2012
Date of Patent:
September 20, 2016
Assignee:
Roche Glycart AG
Inventors:
Oliver Ast, Peter Bruenker, Thomas U. Hofer, Ralf Hosse, Christian Klein, Ekkehard Moessner, Pablo Umana
Abstract: Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.
Type:
Grant
Filed:
February 11, 2013
Date of Patent:
August 30, 2016
Assignee:
City of Hope
Inventors:
John C. Williams, Cindy Zer, Krzysztof Bzymek, Kendra Nicole Avery
Abstract: The invention also relates to a composition comprising an antibody antagonist to c-Met and an aminoheteroaryl compound, particularly as a medicament. The present invention also comprises a pharmaceutical composition comprising said anti c-Met antibody and said aminoheteroaryl compound as combination products for simultaneous, separate or sequential use. The invention relates to the use of the composition of the invention for the treatment of cancer in a mammal.
Abstract: This invention relates to methods and compositions of oligonucleotide constructs having a photocleavable linker. Specifically, provided herein are methods and compositions utilizing a photocleavable linker, which when exposed to light modulates the expression of genes.
Type:
Grant
Filed:
November 27, 2007
Date of Patent:
June 21, 2016
Assignee:
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Abstract: Therapeutic and drug delivery systems are provided in the form of medical devices with coatings for capturing and immobilizing target cells such as circulating progenitor or genetically-altered mammalian cells in vivo. The genetically-altered cells are transfected with genetic material for expressing a marker gene and at least one therapeutic gene in a constitutively or controlled manner. The marker gene is a cell membrane antigen not found in circulating cells in the blood stream and therapeutic gene encodes a peptide for the treatment of disease, such as, vascular disease and cancer. The coating on the medical device may be a biocompatible matrix comprising at least one type of ligand, such as antibodies, antibody fragments, other peptides and small molecules, which recognize and bind the target cells.
Type:
Grant
Filed:
April 29, 2005
Date of Patent:
June 14, 2016
Assignee:
OrbusNeich Medical, Inc.
Inventors:
Michael John Bradley Kutryk, Robert J. Cottone, Jr., Stephen M. Rowland
Abstract: The present invention provides for TLR agonist conjugates (compounds) and compositions, as well as methods of using them. The compounds of the invention are broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal, preferably a human and can help direct the pharmacophore to the receptor within the endosomes of target cells and enhance the signal transduction induced by the pharmacophore.
Type:
Grant
Filed:
November 20, 2012
Date of Patent:
June 7, 2016
Assignee:
The Regents of The University of California
Abstract: The invention provides microparticles or nanoparticles for treatment of tumors comprising: (i) a targeting agent to the tumor or the tumor environment; and (ii) at least one inducer that stimulates a desired immune response in the tumor environment, leading to tumor apoptosis, wherein components (i) and (ii) are non-covalently or covalently attached to the surface of said microparticles or nanoparticles. The targeting agent is an agent that recognizes and binds to an antigen, a receptor or other molecules found on the surface of tumor cells or in the tumor environment and are preferably antibodies.
Type:
Grant
Filed:
January 25, 2009
Date of Patent:
June 7, 2016
Assignees:
GAVISH-GALILEE BIO APPLICATIONS LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Inventors:
Jacob Pitcovski, Ehud Shahar, Raphael Gorodetsky
Abstract: The present invention relates to a novel form of human EGFR found in certain tumors and conditions. The protein is termed here mLEEK, and the cDNA that encodes it has also been isolated. The mLEEK protein is capable of efficiently inducing the transcription of multiple genes resulting in various physiologic processes. Antibodies directed against the protein can be used for improving the diagnosis of diseases or for the treatment of diseases. The protein itself can be directly used or blocked for therapeutic purposes. Nucleic acid based probes or PCR primers specific for the mLEEK sequence can be used for diagnostic purposes. Inhibitory nucleic acid based molecules, such as antisense, siRNA, or shRNA, may be used for therapeutic purposes. The mLEEK sequence is essentially formed by the skipping of exons 2 through 22 in the EGF receptor gene leading to a fusion of exon 1 to exon 23. Other mutants are disclosed, which include the fusion of exon 1 to exon 24 and the fusion of exons 1 to exon 28.
Type:
Grant
Filed:
February 29, 2008
Date of Patent:
May 17, 2016
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: Compositions and methods associated with recurrent MIPOL1-ETV1 genetic rearrangements that are useful for cancer diagnosis and therapy are disclosed.
Type:
Grant
Filed:
July 3, 2008
Date of Patent:
April 5, 2016
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Inventors:
Arul M. Chinnaiyan, Scott Tomlins, Saravana Mohan Dhanasekaran
Abstract: Disclosed are methods and treatment regimes that include the administration of immunconjugates targeting CD138 to combat diseases. The immunoconjugate is either used as the sole active ingredient, as part of a treatment regime or as part of an anticancer combination.
Type:
Grant
Filed:
May 5, 2010
Date of Patent:
March 22, 2016
Assignees:
Biotest AG, Immunogen Inc.
Inventors:
Frank Osterroth, Christoph Uherek, Christoph Bruecher, Benjamin Daelken, Andre Engling, Thomas Haeder, Andrea Wartenberg-Demand, Gabriele Niemann, Chantal Zuber, Niklas Czeloth, Silke Aigner, Steffen Zeng, Gregor Schulz
Abstract: It is an object of the present invention to extend the usefulness of an iron-salen complex. The present invention is a new fluorochrome material containing Chemical Formula (I) below. However, M is Fe, Cr, Mn, Co, Ni, Mo, Ru, Rh, Pd, W, Re, Os, Ir, Pt, Nd, Sm, Eu, or Gd.
Abstract: The present invention is directed to methods for treating cancer comprising administering to a subject in need thereof an auristatin-based antibody drug conjugate and an inhibitor of the PI3K-AKT-mTOR pathway.
Type:
Grant
Filed:
October 20, 2011
Date of Patent:
March 1, 2016
Assignee:
SEATTLE GENETICS, INC.
Inventors:
Timothy S. Lewis, Che-Leung Law, Julie A. McEarchern
Abstract: A process is provided for inhibiting symptoms of food allergy or food intolerance in a subject that includes the oral administration to the subject suffering from food allergy or food intolerance an IgM. When administered in a therapeutic quantity based on the subject characteristics and the type of IgM, symptoms of food allergy or food intolerance in that subject are inhibited. Even non-secretory forms of IgM are effective when administered orally.
Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
Type:
Grant
Filed:
March 11, 2013
Date of Patent:
January 26, 2016
Assignee:
SANOFI
Inventors:
Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
Abstract: The present invention relates to methods and compositions for enhancing delivery of vaccine antigens to the mucosal epithelium, the composition comprising an antigen from an infectious agent fused with an Fc fragment of an immunoglobulin recognized by the neonatal receptors (FcRn). The composition is effective in eliciting a protective long-term memory T cell immune response against infection at a distant mucosal site.
Abstract: The present invention relates to modified therapeutic proteins, such as e.g. coagulation factors. In particular, the present invention relates to conjugated Factor VIII molecules such as e.g. FVII, FVIII, or FIX comprising a hydrophobic side group.
Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
Type:
Grant
Filed:
March 17, 2015
Date of Patent:
January 12, 2016
Assignee:
Immunomedics, Inc.
Inventors:
Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
Abstract: The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders.
Type:
Grant
Filed:
March 11, 2013
Date of Patent:
January 5, 2016
Assignee:
SANOFI
Inventors:
Renata Lee, Vincent Mikol, Elizabeth Allen, Norman Ruetsch, Beatrice Cameron, Thomas Oligino, Nicholas Baurin
Abstract: The invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associated with inappropriate complement activation, and in particular in the treatment of peripheral nerve disorders.
Abstract: This invention provides novel chimeric moieties that show significant efficacy against cancers. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-?).
Type:
Grant
Filed:
September 19, 2008
Date of Patent:
September 22, 2015
Assignee:
The Regents of the University of California
Inventors:
Sherie L. Morrison, Tzu-Hsuan Huang, Caiyun Xuan
Abstract: The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
Type:
Grant
Filed:
April 22, 2014
Date of Patent:
September 22, 2015
Assignee:
Immunomedics, Inc.
Inventors:
Serengulam V. Govindan, Sung-Ju Moon, David M. Goldenberg
Abstract: Described herein are compositions and methods for use in targeted drug delivery using cell receptor binding drug delivery conjugates containing hydrophilic spacer linkers for use in imaging, diagnosing, and/or treating diseases and disease states caused by pathogenic cell populations.
Type:
Grant
Filed:
June 25, 2008
Date of Patent:
September 22, 2015
Assignee:
Endocyte, Inc.
Inventors:
Christopher Paul Leamon, Iontcho Radoslavov Vlahov, Hari Krishna R. Santhapuram, Paul Joseph Kleindl, Yu Wang, Fei You
Abstract: The present invention includes compositions and methods for making and using a drug conjugated to a peptide or protein that binds specifically to a ligand in vivo, wherein the conjugate binds to its ligand in vivo and increases the half-life of the drug.
Abstract: The present invention relates to an activated foam made of a natural or synthetic rubber or a synthetic resin, characterized in that the foam contains a zirconium compound and/or a germanium compound, and has a closed-cell structure, wherein the foam is used so as to directly or indirectly contact with a human body when a pharmaceutical agent is administered. The activated foam can be directly or indirectly contacted with a human body to facilitate blood circulation and promote the improvement of physical condition and the cure of diseases. It also has no adverse effect.
Abstract: The present invention provides a method of treating or preventing the inflammatory response of ulcerative colitis or Crohn's disease in a subject comprising administering to the subject an effective amount of a substance that inhibits the binding of IL-13 to IL-13 receptors on NKT cells or delivers an effector molecule to the NKT cells.
Type:
Grant
Filed:
April 14, 2006
Date of Patent:
July 7, 2015
Assignee:
The United States of America, as represented by the Secretary Department of Health by Human Servies
Inventors:
Warren Strober, Ivan Fuss, Peter Mannon, Jan Preiss, Raj Puri, Koji Kawakami, Stefan Fichtner-Feigl, Atsushi Kitani
Abstract: Disclosed is a liquid formulation of long-acting human growth hormone (hGH) conjugate, free of albumin, which can guarantee the stability of the long-acting hGH conjugate when stored over a long period of time, wherein the long-acting human growth hormone conjugate includes a human growth hormone linked to an immunoglobulin Fc region, and has a prolonged in vivo stability compared to the native form. The liquid formulation of hGH conjugate including a pH 5.0˜6.0 buffer, a sugar alcohol, a salt and a non-ionic surfactant is free of human serum albumin and other hazardous factors which are potentially contaminated with viruses, and can provide excellent storage stability customized for a long-acting hGH conjugate composed of an hGH polypeptide and an immunoglobulin Fc region which has higher molecular weight and in vivo durability, compared to the native.
Type:
Grant
Filed:
July 14, 2011
Date of Patent:
June 23, 2015
Assignee:
HANMI SCIENCE CO., LTD
Inventors:
Sung Hee Hong, Byung Sun Lee, Dae Seong Im, Jae Min Lee, Sung Min Bae, Se Chang Kwon
Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD33. The antibodies are useful for treatment and diagnoses of various cancers as well as detecting CD33.
Type:
Application
Filed:
May 15, 2013
Publication date:
May 28, 2015
Applicant:
SEATTLE GENETICS, INC.
Inventors:
May Kung Sutherland, Maureen Ryan, Django Sussman, Patrick Burke, Scott Jeffrey
Abstract: The present invention is based in part on the discovery of brown and white fat cell specific surface markers. It has been found that the small amino acid transporter Slca10/Asc1 is a specific surface marker for white adipocytes and that the ligand-gated ion channel P2X5 and the small amino acid transporter Slc36a2 are specific surface markers for brown adipocytes. Having identified these specific white and brown cell surface markers, the present invention provides compositions and methods suitable for the targeting of any number of agents to a white or brown adipose tissue and the identification and isolation of white or brown adipocytes for any number of uses including therapeutic, screening and diagnostic purposes.
Abstract: Methods are disclosed for diagnosis, prognosis and therapy of acute myeloid leukemia and myelodysplastic syndromes using interleukin 1 receptor accessory protein and other targets.
Type:
Application
Filed:
August 9, 2012
Publication date:
May 28, 2015
Applicant:
Albert Einstein College of Medicine of Yeshiva University
Inventors:
Ulrich G. Steidl, Laura Barreyro De Pujato, Britta Will
Abstract: The present invention provides compositions and methods for inhibiting the depletion of healthy tissue during CAR T cell therapy. In another embodiment, the invention includes a drug-molecule conjugate which is administered to a subject receiving CAR T cell therapy, where the conjugate binds to the CAR resulting in internalization of the conjugate and inhibition of T cell activity and/or death of the T cell.
Type:
Application
Filed:
July 12, 2013
Publication date:
May 21, 2015
Inventors:
Carl H. June, Bruce L. Levine, Michael D. Kalos
Abstract: The invention relates to the use of an L-ribozyme, which is capable of splitting an L-RNA in the region of a target sequence of the L-RNA, in order to produce a pharmaceutical composition for trating undesired physiological adverse reactions due to the administration of a therapeautic modecule containing the L-RNA. Alternatively, an endogeneous target RNA may also be split by the L-ribozyme.
Abstract: The invention is related to peptide constructs, i.e., polypeptides obtained by linking together two or more peptides based on or derived from different molecules, which are useful in the treatment or prevention of influenza virus and other infectious diseases. Compositions containing the same, methods for producing the same, and methods for using the same are also disclosed, wherein the peptide constructs have the formula P1-x-P2, where P2 is a peptide associated with an infectious agent and P1 is a peptide that will bind to a class of immune cells, such as dendritic cells. The peptide construct can cause the maturation of immature dendritic cells to a more mature state. The peptide construct or the more mature dendritic cell can be administered to a subject to modulate or initiate an immune response against an infectious agent.
Type:
Application
Filed:
May 24, 2012
Publication date:
May 21, 2015
Applicant:
CEL-SCI CORPORATION
Inventors:
Daniel H. Zimmerman, Eyal Talor, Kanta Subbarao, Kobporn Boonnak
Abstract: Compositions and methods used in the non-invasive detection and/or treatment of hypoxic tissues in vivo are described. Compositions including microbubbles functionalized with one or more hypoxia targeting agents and one or more therapeutic compounds, methods of preparing the functionalized microbubbles, and methods of using the functionalized microbubbles for diagnostic and/or therapeutic applications are described, including a method for selectively determining the amount of vascular hypoxia occurring in a tissue.
Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
Type:
Application
Filed:
October 31, 2014
Publication date:
May 21, 2015
Applicant:
BIOGEN IDEC HEMOPHILIA INC.
Inventors:
ROBERT T. PETERS, ADAM R. MEZO, DANIEL S. RIVERA, ALAN J. BITONI, SUSAN C. LOW
Abstract: The invention provides, inter alia, conjugates comprising a coagulating agent conjugated to an antibody, where the antibody specifically binds an extracellular domain epitope of a mammalian PLVAP protein. These agents specifically target HCC tumors and treat the HCC. The invention also provides methods of using these conjugates, such as methods of treating HCC by administering the conjugates provided by the invention or compositions provided by the invention, such as pharmaceutical compositions.
Abstract: The invention relates to an isolated antibody, or fragment thereof, having high affinity for human A? protofibrils. The invention further relates to compositions that include the antibody, or a fragment thereof, and a pharmaceutically acceptable buffer. The invention further relates to a method of preventing or treating Alzheimer's disease, which includes the step of administering to a patient having or suspected of having Alzheimer's disease such an antibody, or fragment thereof or a composition that includes the antibody or a fragment thereof.
Type:
Grant
Filed:
August 26, 2011
Date of Patent:
May 19, 2015
Assignee:
BioArctic Neuroscience AB
Inventors:
Pär Gellerfors, Lars Lannfelt, Dag Sehlin, Frida Ekholm Pettersson, Hillevi Englund
Abstract: The present invention relates to compositions and methods for delivering lysosomal proteins. The compositions and methods described herein permit the targeted delivery of exogenous lysosomal proteins to cell surface proteins that allow their internalization via non-clathrin pathways. The present invention further relates to the use 10 of the compositions and methods for enzyme replacement therapy of lysosomal storage diseases. Nucleic acids, recombinant cells and kits useful for making and using the compositions of the invention are also provided.
Type:
Application
Filed:
October 16, 2014
Publication date:
May 14, 2015
Inventors:
Silvia Muro Galindo, Vladimir R. Muzykantov, Edward Howard Schuchman
Abstract: The invention provides methods and compositions for administration of allogeneic lymphocytes as an an exogenous source of CD4+ T cell help for endogenous, tumor-reactive CD8+ T cells. Depletion of CD8+ T cells from the donor lymphocyte infusion reduces the risk of sustained engraftment and graft-versus-host disease. Removal of regulatory T cells from the infused population may augment the ability of non-regulatory T cells to provide help for endogenous effectors of anti-tumor immunity. Allogeneic T cell therapy is typically given in the context of allogeneic stem cell transplantation, in which the patient receives highly immunosuppressive conditioning followed by an infusion of a stem cell graft containing unselected populations of mature T cells. In the treatment described here, the graft is engineered to minimize the possibility of sustained donor cell engraftment, and the anti-tumor effector T cells derive from the host.
Type:
Application
Filed:
March 15, 2013
Publication date:
May 14, 2015
Inventors:
Ephraim Joseph Fuchs, Heather Jills Symons, Lode Swinnen